Patents Assigned to Institut National de la Sante et de la Recherche Medicale (Inserm)
  • Patent number: 10485516
    Abstract: Method for generating a shear wave in a target region of a soft solid, includes the following steps: a) generating at least two shear waves with a first and a second source of shear waves in the target region; b) detecting a propagation pattern of the shear wave in the target region with a detector unit including a row of ultrasonic transducers aligned on a first direction perpendicular to a detection direction of each or a single ultrasonic transducer movable along a first direction perpendicular to its detection direction; c) proceeding to a time reversal of the detected propagation pattern; and d) submitting the target region to an inverted excitation set of forces based on the temporally inverted propagation pattern. During step b), a first propagation pattern is detected when only the first source is active and a second propagation pattern is detected when only the second source is active.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: November 26, 2019
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), Université Claude Bernard Lyon 1, Centre Léon-Bérard
    Inventors: Stefan Catheline, Remi Souchon, Ali Zorgani, Jean-Yves Chapelon
  • Patent number: 10457678
    Abstract: The present invention relates to new N1- and N7-substituted sibiriline derivatives of the following general formula (I): (I) or a pharmaceutically acceptable salt and/or solvate thereof, notably for use as drug, in particular for use as inhibitor of cellular necroptosis. The present invention also relates to a pharmaceutical composition comprising such a compound and processes to prepare such a compound. The present invention also encompasses the use of a compound of the general formula (I) for organs preservation.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: October 29, 2019
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Sorbonne Universite, Universite Claude Bernard Lyon 1
    Inventors: Marie-Thérèse Dimanche-Boitrel, Stéphane Bach, Claire Delehouze, Peter Goekjian, Arnaud Comte
  • Publication number: 20190307738
    Abstract: The present invention relates to compounds of formula (I) for use as peripheral NMDA receptor antagonists.
    Type: Application
    Filed: June 13, 2017
    Publication date: October 10, 2019
    Applicants: Institut National de la Sante et de la Recherche Medicale (Inserm), Centre National de la Recherche Scientifique (CNRS), Universite Paris SUD, Assistance Publique-Hopitaux de Paris (APHP), Hopital Marie Lannelongue
    Inventors: Sylvia COHEN-KAMINSKY, Marc HUMBERT, Sebastien DUMAS, Gilles BRU-MERCIER, Samir MESSAOUDI, Jean-Daniel BRION, Mouad ALAMI, Gilles GALVANI
  • Patent number: 10436686
    Abstract: The invention relates to a method of separating biological particles from the liquid containing same for purification, analysis and optionally diagnostic purposes. The inventive method comprises at least one step involving vertical filtration through a filter having a porosity that is adapted to the type of biological particles to be separated, such that said particles are retained by the filter. The invention is characterised in that: (i) the method involves the use of a filter comprising at least one basic filtration zone, whereby each basic filtration zone has a limited surface area; and (ii) the surface area of each basic filtration zone and the number of basic filtration zones are selected as a function of the type of liquid to be filtered, the type of biological particles to be separated and the volume of liquid to be filtered.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: October 8, 2019
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, UNIVERSITE RENE DESCARTES-PARIS V
    Inventor: Patrizia Paterlini-Brechot
  • Publication number: 20190298691
    Abstract: The present invention relates to FLT3 receptor inhibitor for use in the treatment of neuropathic pain and chronic pain comprising a neuropathic component, wherein the daily dosage range per human adult per day of said FLT3 receptor inhibitor consists of a dosage range determined by a method comprising the steps of: (i) determining the minimal inhibiting dose of said FLT3 receptor inhibitor that induces the maximal inhibition of mechanical pain hypersensitivity, (ii) converting said dose to the Human Equivalent Dose (HED) by the allometric correction method, and (iii) establishing a daily dosage range per human adult per day wherein (iii-1) the lower limit of the said daily dosage range per human adult per day is the greater value between HED/20 determined via a rat model and 0.001 mg, and (iii-2) the upper limit of the said daily dosage range is the lower value between HED*20 determined via a rat model and 50 mg.
    Type: Application
    Filed: June 8, 2017
    Publication date: October 3, 2019
    Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE MONTPELLIER, BIODOL THERAPEUTICS
    Inventor: Jean VALMIER
  • Patent number: 10426816
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of respiratory tract infections. More particularly, the present invention relates to a TLR5 agonist for use in a method for treating a respiratory tract infection.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: October 1, 2019
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Institut Pasteur de Lille
    Inventors: Jean-Claude Sirard, Jose A. Chabalgoity
  • Patent number: 10426758
    Abstract: The present invention relates to a compound of the following general formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, for use as inhibitor of cellular necroptosis. The present invention also relates to a pharmaceutical composition comprising a compound of general formula (I), or a pharmaceutically acceptable salt and/or solvate thereof, for use for preventing and/or treating disorders associated with cellular necroptosis. The present invention also encompasses the use of a compound of the general formula (I) for organs preservation.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: October 1, 2019
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Universite De Poitiers, Sorbonne Universite, Universite Claude Bernard Lyon 1
    Inventors: Marie-Thérèse Dimanche-Boitrel, Stéphane Bach, Claire Delehouze, Yvette Mettey, Peter Goekjian, Arnaud Comte
  • Patent number: 10420827
    Abstract: The present invention relates to a life attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: September 24, 2019
    Assignees: Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pasteur de Lille, National University of Ireland Maynooth
    Inventors: Camille Locht, Bernard Mahon, Heather Kavanaugh
  • Patent number: 10400284
    Abstract: The present invention relates to a method for predicting whether a patient with a cancer is likely to respond to an epidermal growth factor receptor (EGFR) inhibitor, which method comprises determining the expression level hsa-miR-31-3p miRNA in a sample of said patient. The invention also relates to therapeutic uses of an EGFR inhibitor in a patient predicted to respond to said EGFR inhibitor.
    Type: Grant
    Filed: November 23, 2012
    Date of Patent: September 3, 2019
    Assignees: INTEGRAGEN, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, UNIVERSITE PARIS DESCARTES
    Inventors: Thomas Rio Frio, Pierre Laurent-Puig, Sandrine Imbeaud
  • Patent number: 10394010
    Abstract: An optical system for shaping a wavefront of an electric field of an input light beam to be projected into a target volume including a first optical element, a spatial light modulator used to control light distribution in at least one transverse plane in the target volume. An intermediate optical element located on an optical axis, after the first optical element on a trajectory of the light beam for modulating the phase or the amplitude of the electric field of the input light beam is included. A second optical element for modulating the phase or the amplitude of the electric field of the input light beam is used to control the axial position of the transverse plane in the target volume. The second optical element is situated on the optical axis after the at least one intermediate optical element on the trajectory of the light beam.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: August 27, 2019
    Assignees: UNIVERSITE PARIS DESCARTES, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE(INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Oscar Hernandez-Cubero, Eirini Papagiakoumou, Emiliani Valentina
  • Patent number: 10385125
    Abstract: The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof. The present disclosure is further directed to methods comprising detection of progastrin, including methods of diagnosing colorectal cancer and methods of monitoring efficacy of anti-cancer therapy in subjects suffering from colorectal cancer.
    Type: Grant
    Filed: March 6, 2017
    Date of Patent: August 20, 2019
    Assignees: Les Laboratoires Servier, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS)
    Inventors: Julie Pannequin, Laure Boudier, Dominique Joubert, Frédéric Hollande
  • Patent number: 10385126
    Abstract: The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof. The present disclosure is further directed to methods comprising detection of progastrin, including methods of diagnosing colorectal cancer and methods of monitoring efficacy of anti-cancer therapy in subjects suffering from colorectal cancer.
    Type: Grant
    Filed: March 6, 2017
    Date of Patent: August 20, 2019
    Assignees: Les Laboratoires Servier, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS)
    Inventors: Julie Pannequin, Laure Boudier, Dominique Joubert, Frédéric Hollande
  • Patent number: 10377821
    Abstract: The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof. The present disclosure is further directed to methods comprising detection of progastrin, including methods of diagnosing colorectal cancer and methods of monitoring efficacy of anti-cancer therapy in subjects suffering from colorectal cancer.
    Type: Grant
    Filed: March 6, 2017
    Date of Patent: August 13, 2019
    Assignees: Les Laboratoires Servier, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS)
    Inventors: Julie Pannequin, Laure Boudier, Dominique Joubert, Frédéric Hollande
  • Patent number: 10376484
    Abstract: The present invention relates to the combined use of bezafibrate and of resveratrol or resveratrol derivatives for the treatment of diseases involving a mitochondrial energy dysfunction, and also to a pharmaceutical kit comprising both bezafibrate and resveratrol or resveratrol derivatives. The combination is more particularly used in the treatment of moderate defects of ?-oxidation of long-chain fatty acids or of the respiratory chain of mitochondria.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: August 13, 2019
    Assignees: Institut National de la Santé et de la Recherche Médicale (INSERM), Universite Paris Descartes
    Inventors: Jean Bastin, Fatima Djouadi
  • Patent number: 10370444
    Abstract: The present disclosure provides methods and compositions useful for preventing gastrointestinal and/or colorectal cancer in animals, including humans, having pre-cancerous adenomatous polyps. The present disclosure provides compositions comprising anti-PG antibodies suitable for use in the methods of the disclosure. The present disclosure also provides methods and compositions useful for monitoring the efficacy of anti-PG treatment in subjects with pre-cancerous polyps.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: August 6, 2019
    Assignees: Les Laboratoires Servier, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS)
    Inventors: Leila Houhou, Mathieu Petremann, Dominique Joubert, Frédéric Hollande
  • Patent number: 10358477
    Abstract: The present invention relates to the stimulation of the IL-15Rbeta/gamma signalling pathway, to thereby induce and/or stimulate the activation and/or proliferation of IL-15Rbeta/gamma-positive cells, such as NK and/or T cells. Appropriate compounds include compounds comprising at least one IL-15Rbeta/gamma binding entity, directly or indirectly linked by covalence to at least one polypeptide which contains the sushi domain of the extracellular region of an IL-15Ralpha.
    Type: Grant
    Filed: October 6, 2006
    Date of Patent: July 23, 2019
    Assignee: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Yannick Jacques, Ariane Plet, Erwan Mortier, Agnes Quemener, Patricia Vusio
  • Patent number: 10351623
    Abstract: The invention relates generally to antagonists of IL-17 isoforms and their uses in diagnosis and therapy, especially for the treatment or prevention of cancers or autoimmune and chronic inflammatory diseases.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: July 16, 2019
    Assignees: Orega Biotech, Institut National de la Sante et de La Recherche Medicale (INSERM)
    Inventors: Gilles Alberici, Jeremy Bastid, Armand Bensussan, Nathalie Bonnefoy, Jean-Francois Eliaou
  • Publication number: 20190201492
    Abstract: The present invention concerns a thermosensitive polymeric hydrogel comprising at least one thermosensitive copolymer, one aqueous solution, and a mucoadhesive excipient, wherein said thermosensitive polymeric hydrogel further comprises at least one immunostimulatory adjuvant and/or at least one cytokine and/or at least one chemokine and/or atleast one heat shockprotein. Another object of the invention is a thermosensitive polymeric hydrogel according to the invention for use in the treatment of tumors or metastasis in a subject having a cancer, preferably a metastatic cancer.
    Type: Application
    Filed: August 31, 2017
    Publication date: July 4, 2019
    Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Universite Paris Descartes, Assistance Publique - Hopitaux de Paris, Ecole Nationale Superieure de Chimie de Paris, Universite de Versailles-St Quentin en Yvelines
    Inventors: Robert Malafosse, Nathalie Mignet, Vincent Boudy, Johanne Seguin, Kathia Lemdani, Claude Capron
  • Publication number: 20190201513
    Abstract: Described herein are anti-CD277 antibodies which: activates or inhibit the cytolytic function of V?9/V?2 T cells, and/or costimulates T cells together with CD3-TCR, and/or costimulates T cells in addition to CD28-B7 costimulation, and/or increases the activity and/or survival of monocytes and dendritic cells. The use of said antibodies in therapy is also described.
    Type: Application
    Filed: February 22, 2019
    Publication date: July 4, 2019
    Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), Universite D'Aix-Marseille, Institut Jean Paoli & Irene Calmettes, Centre National De La recherche Scientifique (CNRS), Universite De Nantes
    Inventors: Daniel OLIVE, Marc BONNEVILLE, Emmanuel SCOTET, Christelle HARLY, Yves GUILLAUME
  • Patent number: 10337008
    Abstract: The present invention relates to a method for predicting the progression of chronic kidney disease (CKD) in a patient and also to an inhibitor of NGAL gene expression or an NGAL antagonist for use in the prevention or the treatment of CKD.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: July 2, 2019
    Assignee: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Fabiola Terzi, Amandine Viau, Clément Nguyen, Martine Burtin, Khalil El Karoui